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Abstract 
Introduction: 
There is practice variability in the treatment of patients with minor ischemic stroke with thrombolysis. We 
sought to determine which clinical factors physicians prioritize in thrombolysis decision-making for minor stroke 
using adaptive conjoint analysis. 
Methods: 
We conducted our conjoint analysis using the Potentially All Pairwise RanKings of all possible Alternatives 
methodology via the 1000Minds platform to design an online preference survey and circulated it to US 
physicians involved in stroke care. We evaluated 6 clinical attributes: language/speech deficits, motor deficits, 
other neurological deficits, history suggestive of increased risk of complication from thrombolysis, age, and 
premorbid disability. Survey participants were asked to choose between pairs of treatment scenarios with 
various clinical attributes; scenarios automatically adapted based on participants’ prior responses. Preference 
weights representing the relative importance of each attribute were compared using unadjusted paired t tests. 
Statistical significance was set at α = .05. 
Results: 
Fifty-four participants completed the survey; 61% were vascular neurologists and 93% worked in academic 
centers. All neurological deficits were ranked higher than age, premorbid status, or potential contraindications 
to thrombolysis. Differences between each successive mean preference weight were significant: motor (31.7%, 
standard deviation [SD]: 9.5), language/speech (24.1%, SD: 9.6), other neurological deficits (16.6%, SD: 6.4), 
premorbid status (12.9%, SD: 6.6), age (10.1%, SD: 6.3), and potential thrombolysis contraindication (4.7%, SD: 
4.4). 
Conclusion: 
In a conjoint analysis, surveyed US physicians in academic practice assigned greater weight to motor and 
speech/language deficits than other neurological deficits, patient age, relative contraindications to thrombolysis, 
and premorbid disability when deciding to thrombolyse patients with minor stroke. 
Keywords clinical decision-making, acute ischemic stroke, minor stroke, conjoint analysis 
Introduction 
Thrombolysis treatment rates for patients with acute ischemic stroke presenting with minor symptoms have 
increased over time1 due to recognition of the disability associated with failure to treat and the relative safety of 
thrombolysis in minor stroke.2 Labeling information for alteplase no longer lists minor symptoms as an exclusion 
criterion,3 and the latest guidelines from the American Heart Association/American Stroke Association note that 
alteplase should not be withheld from otherwise eligible patients with mild but disabling strokes.3 However, the 
most commonly documented reason for failure to treat with alteplase is having mild or rapidly improving stroke 
symptoms.4 
A better understanding of clinical decision-making in minor stroke is needed to clarify current treatment 
patterns and facilitate targeted interventions to reduce variability.5 Controversy exists among physicians 
regarding what constitutes a disabling minor deficit.5,6 Additionally, empiric data regarding the risk-to-benefit 
ratio of thrombolysis in patients with nondisabling mild stroke symptoms are limited.3,7 A recent randomized 
controlled trial of alteplase among patients with minor stroke without clearly disabling symptoms, The Potential 
of rtPA for Ischemic Strokes With Mild Symptoms (PRISMS) trial, was terminated early due to slow 
recruitment.8 We, therefore, conducted a survey study using adaptive conjoint analysis (CA) to evaluate how 
physicians weigh various clinical features when deciding whether or not to thrombolyse patients with minor 
stroke. 
Methods 
Conjoint analysis studies are implemented to quantitatively understand how decision makers consider and 
balance various aspects of a complex decision. Acute stroke thrombolysis decision-making is known to 
incorporate many factors,9,10 making it a process well suited to CA. These analytical models are being 
increasingly used to understand decisions in the health-care environment via surveys directed toward patients, 
physicians, and other stakeholders to determine participants’ stated preferences over a range of 
attributes.11 Unlike more traditional vignette studies where a finite number of vignettes are constructed via 
variation of selected attributes that are then presented to subgroups of participants,9,10,12 CA studies evaluate 
trade-offs in an individual’s decision-making based on the interplay of all factors or attributes included in the 
survey.13 A CA can thus be used to discover the relative importance of factors involved in a complex decision to a 
stakeholder.11,13 
We used the Potentially All Pairwise RanKings of all possible Alternatives (PAPRIKA) method to construct our CA 
via the 1000Minds online software platform. This method determines participants’ preference values (weights) 
by asking simple questions involving trade-offs between attributes included in the survey. In economics and 
other social sciences, an individual’s preferences correspond to their underlying utility or desire for an option. 
There are, broadly speaking, 2 types of preferences: revealed and stated. Revealed preferences are derived from 
actual observed market activities, whereas stated preferences can be derived from surveys. The key principle 
behind the PAPRIKA method is that by repeatedly asking participants to choose 1 alternative from a set of 2 
options, eventually enough information about their stated preferences will be generated to accurately rank all 
the attributes under consideration. Choosing between 2 alternatives is easier than choosing 1 alternative from 
among 3 or more options. The PAPRIKA method thus simplifies decision-making while still allowing the relative 
importance of each attribute included in the survey to each participant to be determined.14 
Survey Design 
Our preference survey contained 6 patient-level attributes with 2 to 5 levels each (Table 1): language/speech 
(communication) deficits, motor deficits, and other neurological deficits (sensory loss, quadrantanopia, single 
limb ataxia, and neglect), history suggestive of potential increased risk of thrombolysis complication, age, and 
premorbid disability. Attributes were chosen based on prior research available at the time of study design. We 
selected neurological symptoms across different domains with low National Institutes of Health Stroke Scale 
(NIHSS) in keeping with the definition of minor stroke as NIHSS ≤315 and an earlier physician survey which found 
that cases where NIHSS ≤2 had poor physician consensus.12 Another prior survey study found that premorbid 
status and age greater than 80 were factors that influenced alteplase use16; patient age and cognitive status also 
played a role in thrombolysis decision-making in a recent UK study.13 We selected relative treatment 
contraindications (non-ST-segment elevation myocardial infarction in previous 3 months and genitourinary 
bleeding in the previous 21 days) that physicians reported being willing to disregard when surveyed.17 Given our 
focus on trade-offs between attributes, we sought to avoid extreme values (eg, advanced dementia or active 
bleeding) when constructing our survey study to avoid biasing our results.11 
Table 1. Survey Attributes and Levels. 
   Levels    
  Low Medium  High  
 Communication 
deficit 
Trace 
dysarthria 
Mild dysarthria  Mild aphasia  
 Motor deficit Isolated 
facial droop 
Isolated 
nondominant 
hand weakness 
Isolated 
dominant 
hand 
weakness 
Mild arm and 
mild leg 
weakness 
Truncal 
ataxia 
leading 
to 
inability 
to walk 
Attributes Other 
neurological 
deficit 
Mild 
unilateral 
sensory loss 
Quadrantanopia Single 
limb 
ataxia 
Visual or 
sensory 
neglect 
 
 Relative 
intravenous 
alteplase 
treatment 
contraindication 
 Non-ST-segment 
elevation 
myocardial 
infarction 
(NSTEMI) in 
previous 3 months 
 Genitourinary 
bleeding in 
previous 21 
days 
 
 Age (years) 75 81  92  
  
Premorbid 
functional status 
Fully 
independent 
Needs help paying 
bills 
Needs a 
cane to 
ambulate 
Needs a 
walker to 
ambulate 
 
 
Survey participants were informed prior to starting our survey that questions would involve trade-offs between 
clinical attributes, that their answers depend on personal opinion, and that each question is unique. Participants 
were then presented with thrombolysis treatment scenarios (eg, 92-year-old with isolated nondominant hand 
weakness versus 75-year-old with mild aphasia) based on a combination of 2, and only 2, attribute levels. They 
were asked “which of these 2 (hypothetical) alternatives do you prefer to treat with intravenous-type 
plasminogen activator (tPA)? (all else being equal)” for each scenario set. Participants could select either 
scenario or “they are equal” (Supplemental Figure 1). We imposed some constraints on the survey design to 
prohibit treatment scenarios with deficits that did not fit a typical single vascular syndrome (eg, ataxia and 
aphasia) or where total NIHSS >3. The attributes and levels presented in a treatment scenario automatically 
adapted based on a participant’s prior choices. Each time a participant selected 1 option from a pair of 
hypothetical alternatives, the PAPRIKA method was applied to immediately identify all other pairs of alternatives 
that could be ranked based on that selection and eliminated those scenarios from being presented; primarily, 
the logical property of transitivity was used. The number of questions presented to each survey participant 
therefore was variable based on their individual choices. 
Participant Recruitment 
We recruited physicians treating patients with acute stroke in the US via StrokeNET (Regional Coordinating 
Center Principal Investigators and to their spoke investigators)18 as well as via the official e-mail listings of 
vascular neurology fellowship directors, neurocritical care physicians, and emergency department physicians 
(total N = 853). The survey was opened for participation in January 2017 and closed in July 2017. Participants 
consented to our study by clicking on the hyperlink displayed in the survey invitation. Each participant was 
instructed to complete the survey only once. Participants completed a brief demographics questionnaire once 
they finished the preference survey. The Montefiore Medical Center institutional review board (no.: 2016-6921) 
approved this study. 
Statistical Analysis 
Stated participant preferences (weights) were generated using the PAPRIKA method to represent the relative 
importance of each attribute for each decision maker. Overall mean preference values with standard deviation 
(SD) and mean rank are reported for all included attributes. We used unadjusted paired t tests to compare mean 
preference values. Marginal rate of substitution, the rate at which a participant will substitute one attribute in 
exchange for another while maintaining the same level of utility, was determined. We used Kendall coefficient 
of concordance to assess agreement among all participants (1 = perfect agreement, 0 = perfect disagreement) 
across all possible alternatives. The threshold for statistical significance allowed for an α error of .05. 
Results 
Among 94 individuals who selected the survey link, 54 participants completed the survey in full. Among these 54 
participants, 59% were male, 61% were vascular neurologists, 93% worked in academic centers, and 52% had 
been in practice for more than 10 years (Table 2). The median number of questions presented to each 
participant was 27 (interquartile range: 21-32); the number of questions did not exceed 49 for any participant. 
The survey took an average of 9 minutes to complete; the questionnaire following the survey took an average of 
58 seconds to complete. 
Table 2. Participant Questionnaire.a 
 N (%) 
Level of training  
Resident 1 (1.9) 
Vascular neurology fellow 2 (3.7) 
Other fellow 1 (1.9) 
<5 years in practice 13 (24) 
5-15 years in practice 19 (35.2) 
>15 years in practice 18 (33.3) 
Sex  
Female 22 (40.7) 
Specialty  
Neurology resident 1 (1.9) 
Neurocritical care 10 (18.5) 
Vascular neurology 33 (61.1) 
Emergency medicine 7 (13.0) 
Otherb 3 (5.6) 
Hospital setting  
Academic 50 (92.6) 
Community 4 (7.4) 
US location  
Northeastern 13 (24.1) 
Midwestern 17 (31.5) 
Southern 18 (33.3) 
Western 6 (11.1) 
Career alteplase treatment volume  
None 2 (3.7) 
<25 cases 5 (9.3) 
25-100 12 (22.2) 
100-300 12 (22.2) 
>300 23 (42.6) 
a N = 54. b One participant wrote in “neurointerventionalist/neurointensivist.” 
 
The preference weights of each participant and mean weight are depicted in Figure 1. Motor deficits were 
weighted most heavily (31.7%, SD: 9.5) followed by communication deficits (24.1%, SD: 9.6), other deficits 
(16.6%, SD: 6.4), premorbid status (12.9%, SD: 6.6), age (10.1%, SD: 6.3), and history of a potential 
contraindication to thrombolysis (4.7%, SD: 4.4). The difference between successive mean preference values 
was significant: communication versus motor deficits (P < .001), communication versus other neurological deficit 
(P < .001), other neurological deficits versus premorbid status (P < .01), premorbid status versus age (P = .02), 
and age versus history of potential contraindication (P < .001). 
 
Figure 1. Radar chart depicting all attribute weights; thick black line and percentages represent mean values. 
The mean rank of each of the 6 attributes was as follows: motor deficit = 1.6, communication deficit = 2.3, other 
deficit = 3.2, premorbid functional status = 3.9, age = 4.4, and relative alteplase contraindications = 5.5. The 
marginal rate of substitution of communication deficit for motor deficit was 1.3; the marginal rate of 
substitution of relative contraindication for thrombolysis treatment for motor deficit was 6.8 (Table 3). Kendall 
coefficient of concordance was .80 for all possible alternatives among all participants. 
Table 3. Marginal Rate of Substitution (Ratio) of the Column Attribute for the Row Attribute. 
 Motor 
Deficit 
Communication 
Deficit 
Other 
Neurological 
Deficit 
Premorbid 
Functional 
Status 
Age Relative 
Contraindication 
Motor deficit  1.3 1.9 2.5 3.1 6.8 
Communication 
deficit 
0.8  1.5 1.9 2.4 5.2 
Other neurological 
deficit 
0.5 0.7  1.3 1.6 3.6 
Premorbid functional 
status 
0.4 0.5 0.8  1.3 2.8 
Age 0.3 0.4 0.6 0.8  2.2 
Relative intravenous 
alteplase treatment 
contraindication 
0.1 0.2 0.3 0.4 0.5  
 
Discussion 
In an adaptive CA, we found that experienced, academic physicians practicing in the US consistently weigh 
motor and communication deficits more heavily than other neurological deficits, age, premorbid functional 
status, and potential contraindications for thrombolysis decision-making in patients with minor ischemic stroke. 
We are not aware of any prior studies focused exclusively on minor stroke thrombolytic decision-making that 
use CA or other discrete-choice experimentation. A recent large, systematic US physician vignette survey 
regarding minor stroke treatment decision-making which included 7 clinical patient attributes failed to account 
for more than a small portion of the variance related to alteplase treatment.10 None of the 4 attributes of 
highest relative importance (previous intracerebral hemorrhage, recent anticoagulation, NIHSS score, and 
previous ischemic stroke) in this recent study were included in our CA making cross-study comparisons 
challenging.10 A smaller pilot survey on which the aforementioned recent large physician survey was based upon 
found that physicians were more likely to thrombolyse patients with minor stroke with language/neglect 
symptoms than with motor and visual/spatial/ataxia symptoms.12 The different prioritization of deficit types by 
participants in our study may stem from the fact that we intentionally included patients with very minor 
syndromes (eg, isolated nondominant hand weakness) in our scenarios. A CA evaluating thrombolysis decision-
making in the United Kingdom found significant heterogeneity among physician respondents on the influence of 
NIHSS 2 with aphasia versus NIHSS 5 without aphasia on thrombolysis decision-making, but other neurological 
deficits among patients with minor stroke were not evaluated.13 
Our work adds to the extant literature by suggesting that physician decision-making in minor stroke at academic 
centers is more heavily influenced by the type of neurological deficit a patient presents with rather than 
physician concerns regarding potential treatment complications, age, or premorbid status. It is important to 
note that we did not evaluate how strong alteplase treatment exclusions (eg, active internal bleeding) affects 
decision-making in minor stroke and cannot comment on how including such an attribute would change our 
results. Future CA studies evaluating stroke decision-making may benefit from including different patient 
features or focusing on physician attributes, so that variance in minor stroke treatment can be further 
explained.10 Characterizing physicians’ motivation to withhold thrombolysis in minor stroke (eg expected 
recovery without treatment or meaningfulness of current deficit) is also an area for future research. 
This study has some important limitations. First, we do not know the number of individuals who received our 
survey invite nor do we know the characteristics of physicians who started but did not complete it. This missing 
information prohibits us from reporting our survey response rate, thereby limiting our ability to generalize our 
findings without bias. Additionally, our final sample size is small and our results may not be applicable to 
nonacademic centers outside of the US given the makeup of our participants. Second, we did not include any 
patient neuroimaging or angiographic features in our survey nor did we include patient gender or race/ethnicity. 
Physician-level factors and patients’ preferences are also probably important in minor stroke decision-making 
given the potential for patient–practitioner discordance regarding deficit significance.6 We only include clinical 
patient factors in our survey. Third, we did not include the option of treating with tenecteplase tissue-type 
plasminogen activator (TNK-tPA) despite its favorable safety profile compared to alteplase among patients with 
minor stroke and intracranial occlusion.19 Future minor stroke treatment decisions will likely be informed by 
results from the ongoing TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion 2 
trial as well as the publication of PRISMS.8 
Conclusion 
In a CA of thrombolysis decision-making in patients with minor stroke, surveyed academic US physicians 
consistently assigned greater weight to motor and communication deficits than other neurological deficits, 
patient age, premorbid functional status, and relative treatment contraindications. Additional sources of 
treatment variation among patients with minor stroke should be sought to identify opportunities for 
improvement in stroke decision-making. 
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